Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach Patients Sooner In The United States Than In Europe
The US Food and Drug Administration is often criticized as inefficient compared to its European counterpart, the European Medicines Agency. This criticism is especially common in the field of oncology, where severely ill patients have few therapeutic options. We conducted a direct drug-to-drug comparison of the two regulatory agencies’ approvals of new oncology drugs. We found that contrary to public assertions, the median time for approval for new cancer medicines in the United States was just six months—and that these new anticancer medicines are typically available in the United States before they are in Europe. Our findings reinforce the need for strong financial and public support of the Food and Drug Administration, so that such medicines can continue to be made available speedily to patients in need.
Related posts:
- Share of Cost, Bristol-Myers Squibb And ADAP Crisis Task Force Announce Enhanced, Multi-year Support For AIDS Drug Assistance Programs (ADAPs) In The United States Bristol-Myers Squibb Company (NYSE: BMY) and the ADAP Crisis Task Force (ACTF) announced an enhanced agreement to support the efforts of AIDS Drug Assistance Programs (ADAPs) to provide antiretroviral medicines to people living with HIV and AIDS....
- Joint Statement On The European Union – United States Development Dialogue On the 14 June, the United States (US) and the European Union (EU) met to discuss cooperation and collaboration on development assistance in the second US-EU High Level Consultative Group Meeting since the 2009 re-launch of the US-EU Development Dialogue....
- Share of Cost, Mass. Docs Will Soon Track Patients Who Abuse Prescription Drugs; Wis. Catholic Church Employees Now Eligible For Birth Control The Boston Globe: “With a few computer keystrokes, Massachusetts physicians will soon be able to identify patients who travel from clinic to clinic in pursuit of potent prescription drugs that feed lethal addictions....
- California Share of Cost, Food Dye Ban Implemented Or Considered By Some Health Authorities After Cancer And Hyperactivity Link Found California Share of Cost, Food Dye Ban Implemented Or Considered By Some Health Authorities After Cancer And Hyperactivity Link Found: After new scientific evidence revealed a possible link between food dyes and childhood cancer and hyperactivity, Australian food authorities are reported to be considering banning food colorings from breakfast cereals and confectionary items. The research […]...
- Share of Cost, Esophageal Cancer Risk Lower Than Expected For GERD Patients Share of Cost, The risk of esophageal cancer among patients who suffer from gastroesophageal reflux disease (GERD) is not as high as many may think, according to new research from University of Michigan gastroenterologists. GERD is considered a relative risk for developing esophageal adenocarcinoma, but the absolute risk is not known, says Joel Rubenstein, M.D., […]...
- Share of Cost, For Acid Reflux Disease Patients, Esophageal Cancer Risk Lower Than Expected Share of Cost, The risk of esophageal cancer among patients who suffer from gastroesophageal reflux disease (GERD) is not as high as many may think, according to new research from University of Michigan gastroenterologists. GERD is considered a relative risk for developing esophageal adenocarcinoma, but the absolute risk is not known, says Joel Rubenstein, M.D., […]...
- FDA Approves NEXIUM(R) I.V. (Esomeprazole Sodium) For The Treatment Of GERD With Erosive Esophagitis In Pediatric And Adolescent Patients AstraZeneca (NYSE: AZN) announced today that the U.S. Food and Drug Administration (FDA) has approved the use of NEXIUM® I.V. (esomeprazole sodium) for Injection for children ages greater than 1 month old for the short-term treatment of gastroesophageal reflux disease (GERD) with erosive esophagitis when oral therapy is not possible or appropriate.1 NEXIUM I.V....
- DBV Technologies Receives IND Clearance From FDA To Begin Clinical Trial In Peanut Allergy DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application....
- PacifiCare Dental Plan, United HealthCare Providers Plan Review Regarding the PacifiCare Dental Insurance Plan (Region 1). This dental plan offers individual and family dental benefits. A family membership covers the head of household including spouse, your children 19 years of age or younger and your children up to age 23 if attending school full time. Your online request must be processed on or […]...
- New Federal Campaign to End Use of Antipyschotic Drugs as Chemical Restraints in Nursing Homes New Federal Campaign to End Use of Antipyschotic Drugs as Chemical Restraints in Nursing Homes...
- Public Reporting On Hospital Process Improvements Is Linked To Better Patient Outcomes The Centers for Medicare and Medicaid Services publicly reports so-called process performance at all U.S. hospitals, such as whether certain recommended treatments are given to specific types of patients. We examined whether hospital performance on key process indicators improved during the three years since this reporting began. We also studied whether or not these changes […]...
- Texas Share of Cost, Axanum And Expanded Nexium Indication Rejected By FDA Texas Share of Cost, Axanum And Expanded Nexium Indication Rejected By FDA: The Food and Drug Administration (FDA), USA has denied approval of AstraZeneca’s Axanum (aspirin plus esomeprazole magnesium) and an expanded indication for AstraZeneca’s Nexium (esomeprazole magnesium). AstraZeneca received a CRL (Complete Response Letter) for the new drug application for Axanum tablets, as well […]...
- Although There Is No Known Link Between Food Coloring And ADHD, Wider Safety Issues Remain When University of Maryland psychologist Andrea Chronis-Tuscano testified before a U.S. Food and Drug Administration (FDA) hearing last March, it changed her mind about possible risks of artificial food coloring for children, and drove her to look more closely at the products in her own pantry that she feeds her kids....
- India Says ‘No’ To Policy That Would Block Access To Affordable Medicines At the United Nations High Level Meeting on HIV and AIDS in early June, India announced that it will not accept data exclusivity, a provision harmful to access to affordable medicines, as part of a free trade agreement (FTA) currently being negotiated with the European Union (EU)....
- Share of Cost, New Rules to Require Equal Visitation Rights for All Hospital Patients Share of Cost, New Rules to Require Equal Visitation Rights for All Hospital Patients: The Centers for Medicare & Medicaid Services has issued new rules for Medicare- and Medicaid-participating hospitals that protect patients’ right to choose their own visitors during a hospital stay, including a visitor who is a same-sex domestic partner. The rules require hospitals […]...